Invitrogen™ Demupitamab Recombinant Monoclonal Antibody

Demupitamab, also referred to as immunoglobulin G1-kappa, is a monoclonal antibody that targets the human epidermal growth factor receptor (EGFR or HER1). The ERBB1 gene, also known as EGFR (Epidermal Growth Factor Receptor), encodes a transmembrane receptor that is a member of the ErbB family of receptor tyrosine kinases (RTKs). This family also includes ErbB2 (HER2), ErbB3 (HER3), and ErbB4 (HER4). ERBB1/EGFR is located on chromosome 7p11.2 and consists of 28 exons. The receptor is activated by binding of specific ligands such as EGF and TGF-alpha, which induces conformational changes leading to dimerization, autophosphorylation, and downstream signaling through pathways such as MAPK, PI3K/AKT, and JAK/STAT. These signaling cascades regulate cell proliferation, survival, and differentiation. Aberrant activation of ERBB1/EGFR, often due to mutations, gene amplification, or overexpression, is implicated in various cancers, particularly non-small cell lung cancer (NSCLC), glioblastoma, and colorectal cancer. Targeted therapies, including tyrosine kinase inhibitors (TKIs) and monoclonal antibodies, have been developed to inhibit ERBB1/EGFR signaling, offering clinical benefits in treating EGFR-driven tumors.